Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)
about
Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytesT cell response to Hu-D peptides in patients with anti-Hu syndromeDegeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humansThymic selection generates a large T cell pool recognizing a self-peptide in humansCross-reactivity between HLA-A2-restricted FLU-M1:58-66 and HIV p17 GAG:77-85 epitopes in HIV-infected and uninfected individualsT cell activity correlates with oligomeric peptide-major histocompatibility complex binding on T cell surfaceEvidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidityMass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.Vitiligo puzzle: the pieces fall in place.MHC-restricted antigen presentation and recognition: constraints on gene, recombinant and peptide vaccines in humans.Human tumor antigens for cancer vaccine development.T-cell recognition of melanoma-associated antigens.Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaCross-reactivity in T-cell antigen recognition.Use of tumour-responsive T cells as cancer treatment.Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor modelsPeptide vaccines for cancer.Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapyPD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 proteinImmunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donorsIdentification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillancThe stimulation of low-affinity, nontolerized clones by heteroclitic antigen analogues causes the breaking of tolerance established to an immunodominant T cell epitope.Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitroInsulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.Tumor immunity and autoimmunity induced by immunization with homologous DNAThe use of endogenous T cells for adoptive transfer.TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potencyMolecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8(+) T-cell responses.High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.Poly-glutamic dendrimer-based conjugates for cancer vaccination - a computational design for targeted delivery of antigens.Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogueUnique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients
P2860
Q22009435-5F4A43C6-AA3A-4084-BEAE-F4957C6AFF3DQ24654675-65946A5D-4DC6-49FC-9FBA-7990D92478E3Q24673373-19AD7573-76C6-4944-A62E-B6C6181BECF6Q24675080-6A934FBE-7CBD-49B9-92A5-3EC6375D0E62Q24802424-F45BC046-A11C-472E-94B6-8D251A8688DBQ27635182-DF9D93CA-8E54-4408-89AA-5832C5CCB779Q28360452-DC6D6809-E69A-4DDE-85EC-CA3FABD87D8EQ30304153-BDC3A54D-245B-4875-9824-37B70B303596Q33344607-D45A9398-3224-4C3C-8AF8-2D5F1048F709Q33646658-A0E0E55D-4898-4524-A810-690BE3CB70F3Q33776127-5C4D8386-5A13-4C9E-B041-CD0F0D5A7074Q33827458-A6AF5B6E-A84E-4BAA-8766-F63BC190C626Q33909760-4231A48C-D72F-4308-8A83-9E9962B213B0Q34111789-6EF80969-B1DC-4FF3-82E8-5558B899A860Q34249351-FCA39D98-2C08-44AB-846F-4939025DD8D3Q34285656-0E1E8F6D-0AEB-4625-8A02-AC8E51028950Q34360520-10D4BF2F-147A-4B4C-AAE8-F8144BD3CC28Q34568992-36F1783D-666F-4FCF-A715-7B94AC2099B7Q34594769-5B830485-7BF7-4549-9B59-8A9F614EB6C4Q34606735-298C2D6A-ED31-43E2-BB71-71C3972C2D88Q34975376-5698E087-7C38-44BD-ADC8-A8F398BB8316Q35146595-0D2CC147-7C4F-46DB-8FF9-71C1368DE72BQ35165666-FE6E27CD-A266-46A9-BD1C-45A20D520AEFQ35880416-0A489443-DF88-4A3C-B1C0-369D6D96BE4FQ36150417-76F14FD2-3424-4469-BF71-E7BB9F91F872Q36375260-7E296AA0-98BC-4DE0-923A-B521CDF001BAQ36375353-098B2956-D451-47A6-8ED2-788DEF31337BQ36376523-74C93273-7B03-40F1-BAE8-B42EDF52B5D8Q36835348-311FEEF4-56C1-4315-8B33-70C9C4091FB4Q36924579-CD2CA299-43D4-47EE-A3AD-4A3A6A567DB3Q37001399-0B6C307F-1013-4F27-9BB3-EC01CBB981C5Q37387673-2DCBFBBD-515C-4CE0-A3BA-C29FEA2E0FC6Q38170503-A4AA8AC8-0903-4D54-91BF-5F24A811D39AQ38671405-09F82667-993E-45A6-8D5E-F4681ADA88F7Q40953830-CCE6AFB0-85CF-4C00-B2D7-F265C72D8BDFQ42947076-55436E52-0B93-49B3-9976-EA541BC0CBE1Q50506338-76573E3C-632B-471E-BAB9-1F93AF497934Q52013647-8691228B-4580-47BB-97D4-8A0624AAC17FQ57209299-DFAE9D85-64B4-4456-88C4-92A72FE3846DQ57810732-193EE102-1587-4524-B525-E2E39CE8D981
P2860
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Identification of epitope mimi ...... -derived peptide MART-1(27-35)
@ast
Identification of epitope mimi ...... -derived peptide MART-1(27-35)
@en
type
label
Identification of epitope mimi ...... -derived peptide MART-1(27-35)
@ast
Identification of epitope mimi ...... -derived peptide MART-1(27-35)
@en
prefLabel
Identification of epitope mimi ...... -derived peptide MART-1(27-35)
@ast
Identification of epitope mimi ...... -derived peptide MART-1(27-35)
@en
P2093
P2860
P356
P1476
Identification of epitope mimi ...... -derived peptide MART-1(27-35)
@en
P2093
Castelli C
Marincola FM
Nishimura MI
Parmiani G
Rivoltini L
Squarcina P
P2860
P304
P356
10.1084/JEM.184.2.647
P407
P577
1996-08-01T00:00:00Z